Stockscreener 앱 받기
99.21
0.31%
-0.31
시장 영업 전:
104.58
5.37
+5.41%
전일 마감가:
$99.52
열려 있는:
$100.32
하루 거래량:
391.03K
Relative Volume:
0.52
시가총액:
$6.38B
수익:
$46.02M
순이익/손실:
$-130.15M
주가수익비율:
-48.57
EPS:
-2.0427
순현금흐름:
$56.08M
1주 성능:
-1.98%
1개월 성능:
-4.40%
6개월 성능:
+27.39%
1년 성능:
+124.05%
1일 변동 폭
$97.45
$101.37
1주일 범위
$97.08
$101.37
52주 변동 폭
$41.28
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
99.21 | 6.38B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com Canada
Protagonist Therapeutics: Q1 Earnings Snapshot - kare11.com
Protagonist Therapeutics, Inc. Q1 2026 Financial Report – SEC Filing, Balance Sheets, and Management Discussion - Minichart
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS - MarketBeat
Milestones and Takeda opt-out reshape Protagonist (NASDAQ: PTGX) outlook - Stock Titan
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out - Stock Titan
Protagonist Therapeutics set to report as blockbuster bets grow - Investing.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MSN Money - MSN
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock - Insider Monkey
331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC - MarketBeat
M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard shows 5.09% stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Vanguard reports 3.53M-share stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo
Blood cancer drug translates into $200 million payday for Bay Area company — and there's more to come - The Business Journals
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC - MarketBeat
UBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
[ARS] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Protagonist Therapeutics (NASDAQ: PTGX) plans 2026 meeting and expanded equity plan - Stock Titan
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Takeda (TAK) and Protagonist Therapeutics Deal Revisited - GuruFocus
Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical - marketscreener.com
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration - Voice of Alexandria
Takeda takes U.S. rights to rusfertide; Protagonist eligible for $475M - Stock Titan
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics Shifts Focus to High Margin Commercial Royalties - HarianBasis.co
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock - Yahoo Finance
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
CEO of Protagonist (NASDAQ: PTGX) makes bona fide share gift - Stock Titan
PTGX News | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
PTGX (Protagonist Therapeutics Inc.) rises 2.17 percent even as Q4 2025 EPS falls far below analyst consensus estimates.Profit Guidance - UBND thành phố Hải Phòng
How (PTGX) Movements Inform Risk Allocation Models - Stock Traders Daily
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 1,750 Shares of Stock - MarketBeat
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares - Investing.com
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares By Investing.com - Investing.com Australia
Protagonist Therapeutics (NASDAQ: PTGX) CFO sells shares to cover RSU taxes - Stock Titan
PTGX (NASDAQ) Form 144: 1,750-share sale noted; insider disposals listed - Stock Titan
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Two new hires get rights to 69,850 Protagonist shares in awards - Stock Titan
PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):